Checkpoint inhibition in practice and in public

Multiorgan toxicity following combination immunotherapy treatment in melanoma

Predicting response to immunotherapy

Editor's Choice for September 2017

Respiratory microbiomes and lung cancer from mining communities

ESMO 2017 highlights on managing difficult to treat cancers

ESMO 2017 roundup with Dr Bishal Gyawali (1/2)

Nivolumab and ipilimumab for metastatic kidney cancer

Biological insight in new drug combinations

Checkmate 238: Adjuvant checkpoint therapy after melanoma resection

New strategies in melanoma care

RANGE trial of ramucirumab for urothelial cancer